Summary

Patient and consumer representatives advising U.S. Food and Drug Administration (FDA) expert panels might actually be a Trojan horse for the pharmaceutical industry, a new study says. These supposedly average-Joe representatives often have ties to advocacy organizations funded by drugmakers, researchers recently reported in the journal Health Affairs Scholar .

AI summaries can be wrong sometimes—always verify important details using the source article.